Non-Small Cell Lung Cancer (NSCLC) Market Opportunities, Trends And Forecast To 2035 Growth Driven By Continued Investment In Cell Therapies, Allogeneic Platforms And Next-Gen Biologics
Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Non-Small Cell Lung Cancer Market by Type of Cancer, Type of Molecule, Type of Drug Class, Type of Therapy, Type of Treatment, Route of Administration, End User, Distribution Channel, Geographical Regions and Leading Players - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering.
The global non-small cell lung cancer market is projected to increase from USD 26.4 billion in 2026 to USD 56.0 billion by 2035, representing a compound annual growth rate of 8.7% during the forecast period. Market expansion is being supported by the growing incidence of lung cancer, wider biomarker testing, continued adoption of targeted therapies and immunotherapies, and a robust late-stage drug development pipeline.
Non-Small Cell Lung Cancer Market Growth and Trends
Non-small cell lung cancer accounts for the majority of diagnosed lung cancer cases worldwide. Smoking, air pollution, environmental exposure and an ageing global population continue to expand the eligible patient population. At the same time, regulatory approvals for biomarker-matched therapies and immune checkpoint inhibitors are reshaping treatment pathways across first-line and later-line settings.
Advances in liquid biopsy, molecular diagnostics and real-time disease monitoring are strengthening precision oncology strategies. Drug developers are also prioritizing combination regimens that pair targeted agents or checkpoint inhibitors with chemotherapy and other treatment modalities. These approaches are intended to improve clinical response, extend disease control and address resistance to existing therapies.
Market growth is expected to remain strong as late-stage candidates advance toward potential approvals and pharmaceutical companies reinforce their oncology portfolios through acquisitions, licensing agreements and strategic collaborations. Biomarker-defined patient segmentation, including EGFR, ALK, ROS1, KRAS and HER2 testing, is anticipated to remain central to commercial and clinical development.
Key Market Growth Drivers
- Rising global incidence of non-small cell lung cancer associated with demographic, lifestyle and environmental factors. Increasing demand for earlier diagnosis, molecular profiling and effective treatment monitoring. Expanding use of EGFR and ALK inhibitors, immune checkpoint inhibitors and other precision oncology therapies. Development of combination regimens designed to improve response rates and overcome treatment resistance. Continued investment in cell therapies, allogeneic platforms and next-generation biologics. Government funding and public-private initiatives supporting cancer research and therapeutic innovation.
Challenges Affecting Market Expansion
High treatment costs continue to restrict access to targeted therapies and immunotherapies in several markets. The need for reliable biomarker testing infrastructure can also increase the complexity, time and expense associated with treatment selection. In addition, acquired resistance to targeted agents and evolving regulatory requirements create development and commercialization challenges.
Patent expirations for first-generation therapies are expected to intensify competition from generic and biosimilar products, placing pressure on pricing in selected segments. Market participants will need to address affordability, diagnostic access, regulatory compliance and supply-chain requirements to capture the full commercial potential of the non-small cell lung cancer treatment market.
Strategic and Competitive Insights
- Shift toward dual-targeted treatment: The market is moving beyond single-agent tyrosine kinase inhibitors toward combination and dual-pathway approaches. The approval of RYBREVANT plus LAZCLUZET for first-line EGFR-mutated non-small cell lung cancer reflects this transition. Investment in resistance-focused assets: Large pharmaceutical companies are placing significant value on precision oncology candidates designed to target secondary resistance mutations. GSK's USD 10.6 billion acquisition of Nuvalent added the late-stage ROS1 inhibitor zidesamtinib and ALK inhibitor neladalkib to its oncology portfolio. Greater supply-chain complexity: Growth in biologics, bispecific antibodies and antibody-drug conjugates is increasing demand for specialty distribution, temperature-controlled logistics and advanced product-handling capabilities.
Recent Non-Small Cell Lung Cancer Deal and Regulatory Activity
- In June 2026, GSK announced its USD 10.6 billion acquisition of Nuvalent, adding zidesamtinib and neladalkib to its late-stage oncology pipeline. In May 2026, Merck received FDA Breakthrough Therapy designation for calderasib in combination with pembrolizumab for first-line advanced or metastatic non-small cell lung cancer. In May 2026, Nuvation Bio announced FDA acceptance of a supplemental New Drug Application for taletrectinib in advanced ROS1-positive disease. In February 2026, the FDA granted accelerated approval to Boehringer Ingelheim's zongertinib for unresectable or metastatic non-squamous non-small cell lung cancer with HER2 mutations. In January 2026, the FDA accepted Summit Therapeutics' Biologics License Application for ivonescimab plus chemotherapy in patients with EGFR-mutated disease following prior tyrosine kinase inhibitor therapy.
Non-Small Cell Lung Cancer Market Segmentation
The market analysis covers squamous cell carcinoma, adenocarcinoma, large-cell carcinoma and large-cell neuroendocrine tumors. It also evaluates small molecules and biologics; monotherapies and combination therapies; and chemotherapy, radiation therapy, targeted therapy, immunotherapy and other treatment options.
Additional segmentation includes oral and parenteral administration, hospitals, homecare and specialty clinics, as well as hospital pharmacies, retail pharmacies and online pharmacies. Geographic coverage includes North America, Europe, Asia-Pacific, the Middle East and North Africa, and Latin America.
Leading Market Segments
Adenocarcinoma currently accounts for the largest share of non-small cell lung cancer market revenue, supported by its incidence among smokers and non-smokers and the strong adoption of biomarker-driven treatments. Squamous cell carcinoma is projected to record comparatively faster growth as its late-stage therapeutic pipeline expands.
Small molecules hold the leading market share due to their established role in targeted treatment and combination regimens. Biologics are expected to register faster growth as immune-based therapies, bispecific antibodies and other precision oncology products gain adoption.
EGFR inhibitors lead the drug-class segment and are expected to retain a strong market position through 2035. Development activity is increasingly focused on next-generation inhibitors designed to address resistance and capture opportunities across second- and third-line treatment settings.
Targeted therapy currently represents the largest treatment segment, reflecting demand for biomarker-matched medicines. Immunotherapy is forecast to grow at a higher rate as checkpoint inhibitors and immunocytokines move into earlier lines of treatment and broader combination strategies.
Regional and Distribution Outlook
North America dominates the global non-small cell lung cancer market due to its advanced healthcare infrastructure, high adoption of innovative oncology therapies, extensive molecular testing and concentration of pharmaceutical and biotechnology companies. Asia-Pacific is expected to register a higher growth rate, supported by a rising diagnosed patient population, increasing healthcare access and expanding oncology investment.
Hospital pharmacies account for more than 65% of the market, reflecting their central role in dispensing complex and high-cost oncology medicines. Retail pharmacies are projected to grow more rapidly as a broader range of approved oral therapies becomes available through community-based distribution channels.
Prominent Companies in the Market
Leading participants include:
- Amgen AstraZeneca Bayer BeiGene Boehringer Ingelheim Eli Lilly Genentech (Roche) GSK Johnson & Johnson Merck Novartis Pfizer
Competitive positioning is increasingly influenced by biomarker coverage, combination-treatment strategies, late-stage pipeline strength, intellectual property and global commercialization capabilities.
Research Coverage and Report Benefits
The report provides more than 253 pages across 24 chapters, covering market sizing, competitive benchmarking, company profiles, patent activity, regional opportunities and industry trends. Forecasts are presented under conservative, base and optimistic scenarios, while market opportunities are assessed across nine major segmentation parameters.
Research findings are supported by interviews with thoracic oncologists, medical oncologists and commercial leaders. Purchasers also receive a presentation insights pack, Excel data packs, a detailed report walkthrough, up to 15% complimentary customization and an update when the purchased report is more than six months old.
The study is designed to support pharmaceutical developers, biotechnology companies, investors, specialty distributors, channel intermediaries and service providers seeking actionable intelligence on the global non-small cell lung cancer market through 2035.
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment